Conshohocken-based TargetX Inc. has spun off a consulting division that works with colleges on campus visits by students and their families.
The 15-year-old privately held company would not disclose financial details of the transaction, only that it would retain a minority stake in the former division, which is being renamed Render Experiences and will continue to operate in Atlanta.
Jeff Kallay, who joined TargetX as its "experience evangelist" in 2006, will be the CEO of Render Experiences.
"We felt that it needed to be its own company with its own brand," TargetX CEO Brian Niles said in a statement.
TargetX will focus on helping colleges recruit students using its customer-relationship management software.
What do former chief executives do? Serve on corporate boards.
Michael R. Dougherty, who was president and CEO of Adolor Corp., in Exton, when it was acquired by Cubist Pharmaceuticals Inc. in 2011, was named to the board of AltheRx Pharmaceuticals, a private drug-development firm, also based in Exton. Dougherty, 55, is also on the boards of Viro- Pharma Inc. and Biota Pharmaceuticals Inc.
Marvin Samson, who had been CEO of Qualitest Pharmaceuticals when it was bought by Endo Health Solutions Inc. in 2010, was named to the board of Antares Pharma Inc., a drug company in Ewing, N.J. Samson, 71, is chairman of the board of trustees of the University of the Sciences in Philadelphia.
Tuesday: Globus Medical, Omega Flex; Wednesday: Hill International, Met-Pro, NuPathe, Nutrisystem, PVR Partners, Universal Health Realty Income Trust; Thursday: Resource Capital .
at 215-854-2980 or firstname.lastname@example.org, or follow on Twitter @PhillyInc. Read his
blog, "PhillyInc," at www.inquirer.com/phillyinc.